Oncotelic Therapeutics reported a net loss of $2.92 million for the nine months ended September 30, 2026, compared to a loss of $1.07 million in the prior year period. The company's balance sheet is dominated by a $388 million investment in GMP Bio at fair value, while it continues to manage significant debt obligations and a working capital deficit.
Oncotelic Therapeutics Chairman and CEO Vuong Trieu Buys $17.8K of Stock
Vuong Trieu, Chairman and CEO, bought 1,044,990 shares of Oncotelic Therapeutics, Inc. at $0.017 a share, worth $17.8K in total on Oct 29, 2026. Shares held after the trade: 95,481,309 (+1.1%).
Oncotelic Therapeutics presented its Partitioned Literature Aggregation (PLA) framework at the 22nd Drug Discovery Strategic Summit. The presentation detailed the use of AI and literature analysis to identify a four-gene mTOR signature for hepatocellular carcinoma and outlined plans for an AI-driven research environment targeting 100 billion protein-related vectors.